NICE rejects Perjeta in post-surgery breast cancer use – again
No other immunotherapies are approved in indication
NICE consulting on first draft decision
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.
Health secretary Jeremy Hunt to launch inquiry